Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FORUM MARKETS IncATNF · Entity 7020 | Chief Scientific Officer | September 04, 2023 | September 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FORUM MARKETS Inc
Report date September 04, 2023 · Filed September 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2033-09-04 | Direct | 15,000 |
Reported balance
After 2023-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-04 · Grant · Acquired 15,000 · Balance 15,000 F1: The Stock Options were granted to the Reporting Person pursuant to the Issuer's First Amended and Restated 2022 Omnibus Incentive Plan in consideration for services to be rendered as Chief Scientific Officer. Exempt from Section 16(b) pursuant to Rule 16b-3. F2: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. |
| Common StockSEC Table I · non-derivative | Direct | 28,023 |
Reported balance
Holding disclosure · report date 2023-09-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 28,023 |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options were granted to the Reporting Person pursuant to the Issuer's First Amended and Restated 2022 Omnibus Incentive Plan in consideration for services to be rendered as Chief Scientific Officer. Exempt from Section 16(b) pursuant to Rule 16b-3.
F2: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2023 Filed Sep 8, 2023 20:00 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-23-075375 · ownership.xml · derivative · entry 2 Rothbard Jonathan B. · CIK 0001833968 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-09-04 F1 · kind: The Stock Options were granted to the Reporting Person pursuant to the Issuer's First Amended and Restated 2022 Omnibus Incentive Plan in consideration for services to be rendered as Chief Scientific Officer. Exempt from Section 16(b) pursuant to Rule 16b-3. F2 · derivative.exercise_date: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:30 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001213900-21-064722 · ownership.xml · derivative · entry 2 Rothbard Jonathan B. · CIK 0001833968 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-12-08 F1 · kind: The Stock Options were granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan in consideration for services to be rendered as Chief Scientific Officer. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3. F2 · derivative.exercise_date: The options vest at the rate of 1/3rd of such options at the date of grant with the remaining options vesting at the rate of 24 equal monthly installments, beginning on the last day of December 31, 2021, and continuing on the last day of each calendar month thereafter, subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:15 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 24,307 | $6.14 | $149,244.98 |
DisclosureSEC source: 0001213900-21-021025 · ownership.xml · nonDerivative · entry 1 Rothbard Jonathan B. · CIK 0001833968 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,449 F1 · kind: Issued in consideration for accrued compensation due for services rendered as Chief Scientific Officer of the Issuer. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. F1 · price: Issued in consideration for accrued compensation due for services rendered as Chief Scientific Officer of the Issuer. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.